COVID-19 Is a Coronary Artery Disease Risk Equivalent and Exhibits a Genetic Interaction With ABO Blood Type
Arteriosclerosis, Thrombosis, and Vascular Biology · 2024
DOI: 10.1161/atvbaha.124.321001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2024. Verfasst von James R Hilser und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population and Public Health Sciences (J.R.H., N.J.S., K.A., F.D.G., H.H., J.A.H., H.A.), Keck School of Medicine, University of Southe…. Hauptthemen laut MEDLINE: COVID-19, ABO Blood-Group System, Coronary Artery Disease, SARS-CoV-2. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIEHS NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: COVID-19 is associated with acute risk of major adverse cardiac events (MACE), including myocardial infarction, stroke, and mortality (all-cause). However, the duration and underlying determinants of heightened risk of cardiovascular disease and MACE post–COVID-19 are not known. METHODS: Data from the UK Biobank was used to identify COVID-19 cases (n=10 005) who were positive for polymerase chain reaction (PCR + )-based tests for SARS-CoV-2 infection (n=8062) or received hospital-based International Classification of Diseases version-10 (ICD-10 ) codes for COVID-19 (n=1943) between February 1, 2020 and December 31, 2020. Population controls (n=217 730) and propensity score—matched controls (n=38 860) were also drawn from the UK Biobank during the same period. Proportional hazard models were used to evaluate COVID-19 for association with long-term (>1000 days) risk of MACE and as a coronary artery disease risk equivalent. Additional analyses examined whether COVID-19 interacted with genetic determinants to affect the risk of MACE and its components. RESULTS: The risk of MACE was elevated in COVID-19 cases at all levels of severity (HR, 2.09 [95% CI, 1.94–2.25]; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Population and Public Health Sciences (J.R.H., N.J.S., K.A., F.D.G., H.H., J.A.H., H.A.), Keck School of Medicine, University of Southern California, Los Angeles.
- Department of Biochemistry and Molecular Medicine (J.R.H., N.J.S., K.A., H.A.), Keck School of Medicine, University of Southern California, Los Angeles.
- Department of Medicine (A.D., A.J.L.), Keck School of Medicine, University of Southern California, Los Angeles.
- Department of Microbiology, Immunology, and Molecular Genetics (A.J.L.), David Geffen School of Medicine of UCLA, CA.
- Department of Human Genetics (A.J.L.), David Geffen School of Medicine of UCLA, CA.
- Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute (W.H.W.T., S.L.H.), Cleveland Clinic, OH.
ORCID-Profile: James R Hilser, Neal J Spencer, Frank D Gilliland, Howard Hu, Arjun Deb, Aldons J Lusis, WH Wilson Tang, Jaana A Hartiala, Stanley L Hazen, Hooman Allayee
Förderung
- NIEHS NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Hilser, J. R., Spencer, N. J., Afshari, K., Gilliland, F. D., Hu, H., Deb, A., Lusis, A. J., Tang, W. H. W., Hartiala, J. A., Hazen, S. L., & Allayee, H. (2024). COVID-19 Is a Coronary Artery Disease Risk Equivalent and Exhibits a Genetic Interaction With ABO Blood Type. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.124.321001
Vancouver
Hilser JR, Spencer NJ, Afshari K, Gilliland FD, Hu H, Deb A, et al. COVID-19 Is a Coronary Artery Disease Risk Equivalent and Exhibits a Genetic Interaction With ABO Blood Type. Arteriosclerosis, Thrombosis, and Vascular Biology. 2024. doi:10.1161/atvbaha.124.321001
BibTeX
@article{Hilser2024,
author = {Hilser, James R and Spencer, Neal J and Afshari, Kimia and Gilliland, Frank D and Hu, Howard and Deb, Arjun and Lusis, Aldons J and Tang, WH Wilson and Hartiala, Jaana A and Hazen, Stanley L and Allayee, Hooman},
title = {COVID-19 Is a Coronary Artery Disease Risk Equivalent and Exhibits a Genetic Interaction With ABO Blood Type},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2024},
doi = {10.1161/atvbaha.124.321001}
}
EUVIMED